Angelika Bongers

Cancer Institute of New South Wales — Australia

Medicine · Health Sciences

11h-index338citations35works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(21), Histone Deacetylase Inhibitors Research(19), Protein Degradation and Inhibitors(13), Acute Lymphoblastic Leukemia research(6), Acute Myeloid Leukemia Research(5)

Publications35 total

Polyamine depletion limits progression of acute leukaemia
International Journal of Cancer·2025· 6 citedOpen Access
The polyamine transporter <scp>ATP13A3</scp> mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma
Molecular Oncology·2025· 7 citedOpen Access
Author response for "The polyamine transporter &lt;scp&gt;ATP13A3&lt;/scp&gt; mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma"
2024
Author response for "The polyamine transporter &lt;scp&gt;ATP13A3&lt;/scp&gt; mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma"
2024
The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma
2024· 4 citedOpen Access
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Journal of Molecular Medicine·2024· 13 citedOpen Access
Data from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S3 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S2 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S4 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S3 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S2 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S1 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Data from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Michelle Haber(33), Murray D. Norris(33), Mawar Karsa(30), Klaartje Somers(29), Michelle J. Henderson(28), Chelsea Mayoh(27), Emma Ronca(25), Andrei V. Gudkov(22), Ruby Pandher(22), Katerina V. Gurova(19), Andrew J. Gifford(19), Alvin Kamili(18), Ricky W. Johnstone(18), Jayne Murray(17), Rachael Terry(17), Anahid Ehteda(17), Laura D. Gamble(17), Natalia Issaeva(17), Katerina I. Leonova(17), Aisling O’Connor(17)